A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma

• Status: RECRUITING
• Trial end date: 2026-12-20

Summary

98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trialthis trail is expected to be finished in 24 months

• Phase: PHASE2

Details

• Lead Sponsor: Shanghai Juncell Therapeutics
• Treatments: Cisplatin; Dacarbazine; Temozolomide